Quantitative measurement of alternatively spliced amyloid precursor protein mRNA expression in Alzheimer's disease and normal brain by S1 nuclease protection analysis

Neurobiol Aging. 1991 Sep-Oct;12(5):585-92. doi: 10.1016/0197-4580(91)90090-7.


We have used an S1 nuclease protection strategy to measure alternatively spliced amyloid precursor protein (APP) mRNAs associated with Alzheimer's disease (AD) to determine whether the expression of either one or more of the transcripts correlate with observed amyloid plaque pathology. Comparison of AD with normal cortex reveals that increasing plaque density parallels an increase in the fraction of APP-695 and a corresponding decrease in APP-770 and 751 mRNA fractions. A specific increase of APP-695, the protease inhibitor-lacking APP RNA form, in those brain regions most involved with amyloid plaque formation, suggests that an imbalance in the protease inhibitor is potentially significant in the disease. These data are consistent with cellular/tissue region-specific regulation of alternative splicing accounting for AD-related changes in the expression of APP mRNA forms.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / metabolism*
  • Alzheimer Disease / pathology
  • Amyloid beta-Protein Precursor / biosynthesis*
  • Brain / metabolism*
  • Brain / pathology
  • Female
  • Gene Expression
  • Humans
  • Male
  • Microtubule-Associated Proteins / biosynthesis
  • Middle Aged
  • RNA / metabolism
  • RNA Splicing*
  • RNA, Messenger / biosynthesis*
  • RNA, Messenger / metabolism
  • Single-Strand Specific DNA and RNA Endonucleases*
  • Transcription, Genetic / physiology


  • Amyloid beta-Protein Precursor
  • Microtubule-Associated Proteins
  • RNA, Messenger
  • RNA
  • Single-Strand Specific DNA and RNA Endonucleases